Drug hypersensitivity reactions involving skin

Handbook of Experimental Pharmacology

Volumn 196, Issue , 2010, Pages 29-55

  Pichler, Werner J ^a   Hausmann, Oliver ^b   Schnyder, Benno ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE

Author keywords

Drug hypersensitivity; Exanthema; Mechanism; P i concept (pharmacological interaction of drugs with immune receptors); T cells

Indexed keywords

ALLOPURINOL; AMINOPENICILLIN; BETA LACTAM ANTIBIOTIC; CD4 ANTIGEN; CD8 ANTIGEN; CELECOXIB; CEPHALOSPORIN DERIVATIVE; CHEMOKINE; CYTOKINE; DILTIAZEM; DIURETIC AGENT; GAMMA INTERFERON; GEMIFLOXACIN; HAPTEN; IMMUNOGLOBULIN E; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LAMOTRIGINE; MACROLIDE; NEVIRAPINE; PARACETAMOL; PHENYTOIN; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMETHOXAZOLE; T LYMPHOCYTE RECEPTOR; TERBINAFINE; UNINDEXED DRUG; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ANAPHYLACTIC SHOCK; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COVALENT BOND; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; DRESS SYNDROME; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; EOSINOPHIL; FATALITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MACULOPAPULAR RASH; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; NEUTROPHIL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SKIN ALLERGY; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SYMPTOM; SYSTEMIC DISEASE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG ERUPTION; DRUG THERAPY; HOSPITALIZATION; IMMUNOLOGY; PATHOLOGY; RECURRENT DISEASE; SIGNAL TRANSDUCTION; SKIN; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; DRUG ERUPTIONS; DRUG THERAPY; HAPTENS; HUMANS; HYPERSENSITIVITY, DELAYED; RECEPTORS, ANTIGEN, T-CELL; RECURRENCE; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SKIN; T-LYMPHOCYTE SUBSETS;

EID: 77949313606     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-00663-0_2     Document Type: Review

References (70)

1. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H (2003) Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 162:1515-1520
2. 2 and 2, 4-dinitrochlorobenzene. J Invest Dermatol 120:390-399
3. Alanore L, Roujeau JC (2007) Clinic and pathogenesis of severe bullous skin reactions: Stevens--Johnson syndrome, toxic epidermal necrolysis. In: Pichler WJ (ed) Drug hypersensitivity. Karger, Basel, pp 267-277
4. Bachot N, Revuz J, Roujeau JC (2003) Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 139:33-36
5. Becker D, Mohamadzadeh M, Reske K, Knop J (1992) Increased level of intracellular MHC class II molecules in murine Langerhans cells following in vivo and in vitro administration of contact allergens. J Invest Dermatol 99:545-549
6. Bowen DG, Zen M, Holz L, Davis T, McCaughan GW, Bertolino P (2004) The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. JClin Invest 114:701-712
7. Britschgi M, Steiner UC, Schmid S, Depta JP, Senti G, Bircher A, Burkhart C, Yawalkar N, Pichler WJ(2001) T-cell involvement in drug-induced acute generalized exanthematous pustulosis. JClin Invest 107:1433-1441
8. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428:486
9. Clark RA, Chong B, Mirchandani N, Brinster NK, Yamanaka K, Dowgiert RK, Kupper TS (2006) The vast majority of CLA+T cells are resident in normal skin. JImmunol 176:4431-4439
10. Coombs PR, Gell PG (1968) Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell RR (ed) Clinical aspects of immunology. Oxford University Press, Oxford, pp 575-596
11. Crispe IN (2003) Hepatic T cells and liver tolerance. Nat Rev Immunol 3:51-62
12. Devillier P (2006) Comparing the new antihistamines: the role of pharmacological parameters. Clin Exp Allergy 36:5-7
13. Enk AH, Katz SI (1992) Early molecular events in the induction phase of contact sensitivity. Proc Natl Acad Sci U S A 89:1398-1402
14. Florvaag E, Johansson SG, Oman H, Harboe T, Nopp A (2006) Pholcodine stimulates a dramatic increase of IgE in IgE-sensitized individuals. A pilot study. Allergy 61:49-55
15. Gerber BO, Zanni MP, Uguccioni M, Loetscher M, Mackay CR, Pichler WJ, Yawalkar N, Baggiolini M, Moser B (1997) Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr Biol 7:836-843
16. Gex-Collet C, Helbling A, Pichler WJ (2005) Multiple drug hypersensitivity-proof of multiple drug hypersensitivity by patch and lymphocyte transformation tests. JInvest Allerg Clin Immunol 15:293-296
17. Girolomoni G, Simon JC, Bergstresser PR, Cruz PD Jr (1990) Freshly isolated spleen dendritic cells and epidermal Langerhans cells undergo similar phenotypic and functional changes during short-term culture. JImmunol 145:2820-2826
18. Griem P, Wulferink M, Sachs B, Gonzalez JB, Gleichmann E (1998) Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today 19:133-141
19. Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, Roujeau JC, Revuz J (2006) Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. JInvest Dermatol 126:272-276
20. Hari Y, Urwyler A, Hurni M, Yawalkar N, Dahinden C, Wendland T, Braathen LR, Matter L, Pichler WJ (1999) Distinct serum cytokine levels in drug- and measles-induced exanthema. Int Arch Allergy Immunol 120:225-229
21. Hari Y, Frutig-Schnyder K, Hurni M, Yawalkar N, Zanni MP, Schnyder B, Kappeler A, von Greyerz S, Braathen LR, Pichler WJ (2001) T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 31:1398-1408
22. Hashimoto K, Yasukawa M, TohyamaM(2003) Human herpesvirus 6 and drug allergy. Curr Opin Allergy Clin Immunol 3:255-260
23. Hulette BC, Ryan CA, Gildea LA, Gerberick GF (2005) Relationship of CD86 surface marker expression and cytotoxicity on dendritic cells exposed to chemical allergen. Toxicol Appl Pharmacol 209:159-166
24. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT (2005) HLA-B allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102:4134-4139
25. Janmohamed A, Dolphin CT, Phillips IR, Shephard EA (2001) Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. Biochem Pharmacol 62:777-786
26. Keller M, Spanou Z, Schaerli P, Britschgi M, Yawalkar N, Seitz M, Villiger PM, Pichler WJ (2005) T cell-regulated neutrophilic inflammation in autoinflammatory diseases. JImmunol 175:7678-7686
27. Kimber I, Cumberbatch M (1992) Dendritic cells and cutaneous immune responses to chemical allergens. Toxicol Appl Pharmacol 117:137-146
28. Knowles SR, Shapiro LE, Shear NH (1999) Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 21:489-501
29. Knowles SR, Uetrecht J, Shear NH (2000) Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 356:1587-1591
30. Kuechler PC, Britschgi M, Schmid S, Hari Y, Grabscheid B, Pichler WJ (2004) Cytotoxic mechanisms in different forms of T-cell-mediated drug allergies. Allergy 59:613-622
31. Landsteiner K, Jacobs J (1935) Studies on the sensitization of animals with simple chemical compounds. JExper Med 61: 643-656
32. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200-1205
33. Lipper GM, Arndt KA, Dover JS (2000) Recent therapeutic advances in dermatology. JAMA 283:175-177
34. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT (2002) Association between presence of HLA-B, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727-732
35. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jagel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, HughesA, Ryan S, Fitch N, Thorborn D, Benbow A (2008) HLA-B screening for hypersensitivity to abacavir. N Engl JMed 358:568-579
36. Mockenhaupt M (2007) Epidemiology and causes of severe cutaneous adverse reactions to drugs. In: Pichler WJ(ed) Drug hypersensitivity. Karger, Basel
37. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. JInvest Dermatol 128:35-44
38. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK (2000) Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 23:483-507
39. Naisbitt DJ, Gordon SF, Pirmohamed M, Burkhart C, Cribb AE, Pichler WJ, Park BK (2001) Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br JPharmacol 133:295-305
40. Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, Gibney CA, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK (2003) Characterization of drug-specific T cells in lamotrigine hypersensitivity. JAllergy Clin Immunol 111:1393-1403
41. Nassif A, Bensussan A, Dorothee G, Mami-Chouaib F, Bachot N, Bagot M, Boumsell L, Roujeau JC (2002) Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. JInvest Dermatol 118:728-733
42. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, Bagot M, Roujeau JC (2004) Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. JAllergy Clin Immunol 114:1209-1215
43. Neisius U, Brand P, Plochmann S, Saloga J, Knop J, Becker D (1999) Detection of increased tyrosine phosphorylation in murine Langerhans cells after stimulation with contact sensitizers. Arch Dermatol Res 291:22-27
44. Neukomm CB, Yawalkar N, Helbling A, Pichler WJ (2001) T-cell reactions to drugs in distinct clinical manifestations of drug allergy. JInvestig Allergol Clin Immunol 11:275-284
45. Peyriere H, Dereure O, Breton H, Demoly P, Cociglio M, Blayac JP, Hillaire-Buys D (2006) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br JDermatol 155:422-428
46. Pichler WJ (2002) Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2:301-305
47. Pichler WJ (2003) Delayed drug hypersensitivity reactions. Ann Intern Med 139:683-693
48. Pichler WJ (2005) Direct T-cell stimulations by drugs-bypassing the innate immune system. Toxicology 209:95-100
49. Pichler WJ (2007) Drug Hypersensitivity reactions: classification and relationship to T-cell activation. In: Pichler WJ (ed) Drug hypersensitivity. Karger, Basel, pp 168-189
50. Pichler WJ, Campi P (2007) Adverse side effects to biological agents. In: Pichler WJ (ed) Drug hypersensitivity. Karger, Basel, pp 151-165
51. Posadas SJ, Pichler WJ (2007) Delayed drug hypersensitivity reactions - new concepts. Clin Exp Allergy 37:989-999
52. Rawlins M, Thompson W (1991) Mechanisms of adverse drug reactions. In: Davies D (ed) Textbook of adverse drug reactions. Oxford University Press, New York, pp 18-45
53. Reilly TP, Lash LH, Doll MA, Hein DW, Woster PM, Svensson CK (2000) A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. JInvest Dermatol 114:1164-1173
54. Roychowdhury S, Svensson CK (2005) Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin. Aaps J7:E834-E846
55. Sanderson JP, Naisbitt DJ, Farrell J, Ashby CA, Tucker MJ, Rieder MJ, Pirmohamed M, Clarke SE, Park BK (2007) Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. JImmunol 178:5533-5542
56. Schmid DA, Campi P, Pichler WJ (2006a) Hypersensitivity reactions to quinolones. Curr Pharm Des 12:3313-3326
57. Schmid DA, Depta JP, Luthi M, Pichler WJ (2006b) Transfection of drug-specific T-cell receptors into hybridoma cells: tools to monitor drug interaction with T-cell receptors and evaluate crossreactivity to related compounds. Mol Pharmacol 70:356-365
58. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ (1997) Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. JClin Invest 100:136-141
59. Schnyder B, Frutig K, Mauri-Hellweg D, Limat A, Yawalkar N, PichlerWJ (1998) T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin Exp Allergy 28:1412-1417
60. Shiohara T, Takahashi R, Kano Y (2007) Drug induced hypersensitivity syndrome and viral infections. In: Pichler WJ(ed) Drug hypersensitivity. Karger, Basel, pp 251-266
61. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC (2001) Acute generalized exanthematous pustulosis (AGEP)-a clinical reaction pattern. JCutan Pathol 28:113-119 (Pubitemid 32112994)
62. Spanou Z, Keller M, Britschgi M, Yawalkar N, Fehr T, Neuweiler J, Gugger M, Mohaupt M, Pichler WJ (2006) Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. JAm Soc Nephrol 17:2919-2927
63. Swanson HI (2004) Cytochrome P450 expression in human keratinocytes: an aryl hydrocarbon receptor perspective. Chem Biol Interact 149:69-79
64. Uetrecht J (2001) Prediction of a new drug's potential to cause idiosyncratic reactions. Curr Opin Drug Discov Devel 4:55-59
65. Verrier AC, Schmitt D, Staquet MJ (1999) Fragrance and contact allergens in vitro modulate the HLA-DR and E-cadherin expression on human epidermal Langerhans cells. Int Arch Allergy Immunol 120:56-62
66. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490-493
67. Wu LC, Tuot DS, Lyons DS, Garcia KC, Davis MM (2002) Two-step binding mechanism for T-cell receptor recognition of peptide MHC. Nature 418:552-556
68. Yang CW, Hung SI, Juo CG, Lin YP, Fang WH, Lu IH, Chen ST, Chen YT (2007) HLA-B-bound peptides: implications for the pathogenesis of carbamazepine- induced Stevens-Johnson syndrome. JAllergy Clin Immunol 120:870-877
69. Yawalkar N, Egli F, Hari Y, Nievergelt H, Braathen LR, Pichler WJ (2000) Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 30:847-855
70. Zanni MP, von Greyerz S, Schnyder B, Brander KA, Frutig K, Hari Y, Valitutti S, Pichler WJ (1998) HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. JClin Invest 102:1591-1598